Curocell, Inc. engages in the development of anticancer immune cell treatments. It specializes in CAR-T cell therapy. The company was founded by Gun-Soo Kim, Hyun-Bo Sim and Chan-Hyuk Kim on December 1, 2016 and is headquartered in Yuseong-gu, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company